J K Pharmachem Ltd

Know More
NSEBSE
Stock not tradded
Stock not tradded

BSE : 500218

NSE : JKPHARMA

Sector : Health care

ISIN Code : INE335C01018

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Market Cap (₹ Cr)

0

Turnover (₹ Cr)

0.00

Volume (Shares)

52-WK High

0.00

52-WK High Date

Invalid date

52-WK Low

0.00

52-WK Low Date

Invalid date

All Time High

32.50

All Time High Date

06 Mar 1995

All Time Low

1.30

All Time Low Date

19 Oct 2001

J K Pharmachem Ltd

Jointly promoted by J K Industries and TIDCO J K Pharmachem manufactures drugs and pharmaceuticals. It entered the capital market in Oct.'94 to part-finance the setting up of a plant to manufacture 1250 MMU P.a of pencillin-G based on a microbial strain from the technical collaborators -- IGC (Cyprus) Cyprus -- a wholly-owned subsidiary of ICN Galenika. Commercial production at this plant commenced in Oct.'95. The company has a tie-up with ICN Galenika part of the ICN Pharmaceuticals group (one of the pioneering manufacturers of pencillin-G) to set up a 1250-mmu capacity plant. It has already produced international standard penicillin with Indian raw materials at its collaborator's plant which is among the best in the world. In addition J K Pharmachem had set-up its own R&D activity well in advance for future development in the field of bio-technology. A pilot plant is also being established for this purpose at Cuddalore Tamilnadu.The company also plans to diversify into speciality fermentation products. It has also started production of Penicillin-V and is the only one in India to produce this bulk active.During 1999-2000 the company started the production of Penicillin V and is the only producer of this important bulk active in India. The accumulated losses of the company having exceeded 50% of the peak networth of the company in the immediately preceding four financial years the company took the necessary steps of SICA 1985. The company developed an in-house and launched viz JKZyme an environment new product of paper & pulp. Commercial trails are under way in India and abroad.The company has produced 1192 MMU of Penicillin-G during the financial year 2003-04 and retained its status as the second largest producer with a market share of 24%.

Announcement

View More

J K Pharmachem Ltd - Key Fundamentals

PARAMETER VALUES
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)
UTI-Conservative Hybrid Fund - (G) 0.00 1382619 0.00
UTI-Conservative Hybrid Fund - (IDCW-M) 0.00 1382619 0.00
UTI-Conservative Hybrid Fund - Monthly Payment 0.00 1382619 0.00
UTI-Conservative Hybrid Fund - Flexi (IDCW) 0.00 1382619 0.00
UTI-Conservative Hybrid Fund - Direct (G) 0.00 1382619 0.00
UTI-Conservative Hybrid Fund - Direct (IDCW-M) 0.00 1382619 0.00
UTI-Conservative Hybrid Fund - Direct (IDCW-Flexi) 0.00 1382619 0.00
UTI-Conservative Hybrid Fund - Direct (Monthly-Paymen) 0.00 1382619 0.00

Research Reports

Date BrokerActionPrices(Rs)Report
Data Not Found

Stock Strength

Year Low/High

0.00

0.00

All time Low/High

1.10

37.00

Share Price Returns

Period BSENSE SENSEXNIFTY
1 Week%%0.800.71%
1 Month%%2.712.69%
3 Month%%6.327.20%
6 Month%%12.0014.21%
1 Year%%23.1927.07%
3 Year%%46.1749.66%

Company Info

Company Information

Director : Deep Chandra Jain

Nominee (UTI) : Kailash Bhansali

Director : Prakash Chandra Jain

Director : Pramod Kapoor

Director : Sudhir A Bidkar

Director : S K Sagar

Nominee (TIDCO) : T S Surendranath

Director : V P Vig

Deputy Company Secretary : Shweta Girotra

Registered Office: A-7 SIPCOT Industrial Complex, South Arcot Dist Vallalar,Cuddalore,Tamil Nadu-607005 Ph: 91-04142-239016-20

Email:

URL: